SCHEMBL1337357

SCHEMBL1337357

COc1ccc(-c2cc3c4ccccc4n(C)c3n(C)c2=O)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.50
▸ KDM4E B2RXH2 5/20 0.50
▸ HPGD P15428 4/20 0.50
▸ L3MBTL1 Q9Y468 3/20 0.50
▸ MAPT P10636 3/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ NTRK1 P04629 3/20 0.47
▸ GAA P10253 3/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.40
▸ APAF1 O14727 1/20 0.40
▸ PABPC1 P11940 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MCL1 Q07820 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338090 0.85 KDM4E (0.52) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL2385324 0.85 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDL3MBTL1MAPT
SCHEMBL1338652 0.83 ATM (0.47) ALDH1A1KDM4EHPGDL3MBTL1HSD17B10
SCHEMBL3867031 0.83 KDM4E (0.51) ALDH1A1KDM4EHPGDL3MBTL1MAPT
SCHEMBL1340064 0.82 MAPT (0.41) ALDH1A1KDM4EHPGDL3MBTL1MAPT
SCHEMBL1338786 0.80 L3MBTL1 (0.50) ALDH1A1KDM4EHPGDL3MBTL1MAPT
SCHEMBL1339300 0.76 MAPT (0.45) ALDH1A1KDM4EHPGDL3MBTL1MAPT
SCHEMBL1339301 0.76 MAPT (0.45) ALDH1A1KDM4EHPGDL3MBTL1MAPT
SCHEMBL1337225 0.76 HPGD (0.42) ALDH1A1KDM4EHPGDL3MBTL1MAPT
SCHEMBL1337392 0.75 HSD17B10 (0.46) ALDH1A1KDM4EHPGDL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 ALDH1A1 283/4885KDM4E 1908/4885HPGD 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback